JP2014526441A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014526441A5 JP2014526441A5 JP2014528614A JP2014528614A JP2014526441A5 JP 2014526441 A5 JP2014526441 A5 JP 2014526441A5 JP 2014528614 A JP2014528614 A JP 2014528614A JP 2014528614 A JP2014528614 A JP 2014528614A JP 2014526441 A5 JP2014526441 A5 JP 2014526441A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- subject
- fgf21
- polypeptide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 32
- 208000030159 metabolic disease Diseases 0.000 claims 12
- 101000846529 Homo sapiens Fibroblast growth factor 21 Proteins 0.000 claims 10
- 102000056713 human FGF21 Human genes 0.000 claims 10
- 108090000376 Fibroblast growth factor 21 Proteins 0.000 claims 9
- 102000003973 Fibroblast growth factor 21 Human genes 0.000 claims 9
- 238000000034 method Methods 0.000 claims 8
- 229920001184 polypeptide Polymers 0.000 claims 6
- 102000004196 processed proteins & peptides Human genes 0.000 claims 6
- 108090000765 processed proteins & peptides Proteins 0.000 claims 6
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims 4
- 241000124008 Mammalia Species 0.000 claims 4
- 210000004369 blood Anatomy 0.000 claims 4
- 239000008280 blood Substances 0.000 claims 4
- 239000008103 glucose Substances 0.000 claims 4
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 claims 4
- 230000035772 mutation Effects 0.000 claims 4
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 2
- 208000032928 Dyslipidaemia Diseases 0.000 claims 2
- 102000004877 Insulin Human genes 0.000 claims 2
- 108090001061 Insulin Proteins 0.000 claims 2
- 208000017170 Lipid metabolism disease Diseases 0.000 claims 2
- 208000008589 Obesity Diseases 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims 2
- 239000003937 drug carrier Substances 0.000 claims 2
- 229940125396 insulin Drugs 0.000 claims 2
- 239000000203 mixture Substances 0.000 claims 2
- 235000020824 obesity Nutrition 0.000 claims 2
- 210000002966 serum Anatomy 0.000 claims 2
- 150000001413 amino acids Chemical group 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161529641P | 2011-08-31 | 2011-08-31 | |
| US61/529,641 | 2011-08-31 | ||
| PCT/US2012/053216 WO2013033452A2 (en) | 2011-08-31 | 2012-08-30 | Method of treating or ameliorating type 1 diabetes using fgf21 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017132449A Division JP2017226665A (ja) | 2011-08-31 | 2017-07-06 | １型糖尿病の治療における使用のためのｆｇｆ２１ |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2014526441A JP2014526441A (ja) | 2014-10-06 |
| JP2014526441A5 true JP2014526441A5 (enExample) | 2015-10-29 |
Family
ID=46964016
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014528614A Pending JP2014526441A (ja) | 2011-08-31 | 2012-08-30 | １型糖尿病の治療における使用のためのｆｇｆ２１ |
| JP2017132449A Pending JP2017226665A (ja) | 2011-08-31 | 2017-07-06 | １型糖尿病の治療における使用のためのｆｇｆ２１ |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017132449A Pending JP2017226665A (ja) | 2011-08-31 | 2017-07-06 | １型糖尿病の治療における使用のためのｆｇｆ２１ |
Country Status (7)
| Country | Link |
|---|---|
| US (2) | US20140213512A1 (enExample) |
| EP (1) | EP2750695A2 (enExample) |
| JP (2) | JP2014526441A (enExample) |
| AU (1) | AU2012301769B2 (enExample) |
| CA (1) | CA2845357A1 (enExample) |
| MX (1) | MX2014002260A (enExample) |
| WO (1) | WO2013033452A2 (enExample) |
Families Citing this family (52)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JOP20190083A1 (ar) | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| JP5767314B2 (ja) | 2010-04-16 | 2015-08-19 | ソーク インスティチュート フォー バイオロジカル スタディーズ | Ｆｇｆを用いて代謝障害を処置するための方法 |
| CA2835607C (en) | 2011-07-01 | 2021-07-20 | Ngm Biopharmaceuticals, Inc. | Compositions, uses and methods for treatment of metabolic disorders and diseases |
| KR20220051197A (ko) | 2012-05-17 | 2022-04-26 | 익스텐드 바이오사이언시즈, 인크. | 개선된 약물 전달용 캐리어 |
| US9290557B2 (en) | 2012-11-28 | 2016-03-22 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants and fusions of FGF19 polypeptides |
| AU2013352363B2 (en) | 2012-11-28 | 2018-04-12 | Ngm Biopharmaceuticals, Inc. | Compositions and methods for treatment of metabolic disorders and diseases |
| US9925242B2 (en) | 2012-12-27 | 2018-03-27 | Ngm Biopharmaceuticals, Inc. | Methods of using compositions comprising variants and fusions of FGF19 polypeptides for treatment of nonalcoholic steatohepatitis |
| US9273107B2 (en) | 2012-12-27 | 2016-03-01 | Ngm Biopharmaceuticals, Inc. | Uses and methods for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2015061331A1 (en) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Chimeric fibroblast growth factor (fgf) 2/fgf1 peptides and methods of use |
| WO2015061361A1 (en) | 2013-10-21 | 2015-04-30 | Salk Institute For Biological Studies | Mutated fibroblast growth factor (fgf) 1 and methods of use |
| JP6560202B2 (ja) | 2013-10-28 | 2019-08-21 | エヌジーエム バイオファーマシューティカルス，インコーポレーテッド | 癌モデル及び関連方法 |
| EP3738981A1 (en) | 2014-01-24 | 2020-11-18 | NGM Biopharmaceuticals, Inc. | Antibodies binding beta klotho domain 2 and methods of use thereof |
| EP3125921B1 (en) | 2014-03-11 | 2020-07-08 | Novartis AG | Fgf21 variants for use in treating hiv-haart induced partial lipodystrophy |
| MX373805B (es) | 2014-03-25 | 2020-03-24 | Regeneron Pharma | Agonistas de receptor fgf21 y usos del mismo. |
| US10398758B2 (en) | 2014-05-28 | 2019-09-03 | Ngm Biopharmaceuticals, Inc. | Compositions comprising variants of FGF19 polypeptides and uses thereof for the treatment of hyperglycemic conditions |
| AU2015277438B2 (en) | 2014-06-16 | 2020-02-27 | Ngm Biopharmaceuticals, Inc. | Methods and uses for modulating bile acid homeostasis and treatment of bile acid disorders and diseases |
| WO2016039339A1 (ja) * | 2014-09-08 | 2016-03-17 | 国立大学法人大阪大学 | 脱髄疾患の予防又は治療剤 |
| WO2016041588A1 (en) | 2014-09-16 | 2016-03-24 | Universitat Autònoma De Barcelona | Adeno-associated viral vectors for the gene therapy of metabolic diseases |
| WO2016048999A2 (en) * | 2014-09-23 | 2016-03-31 | Salk Institute For Biological Studies | Fgf21 truncations and mutants and uses thereof |
| WO2016065052A1 (en) | 2014-10-22 | 2016-04-28 | Extend Biosciences, Inc. | Insulin vitamin d conjugates |
| US9789197B2 (en) | 2014-10-22 | 2017-10-17 | Extend Biosciences, Inc. | RNAi vitamin D conjugates |
| CA2964463C (en) | 2014-10-22 | 2024-02-13 | Extend Biosciences, Inc. | Therapeutic vitamin d conjugates |
| SG11201702757YA (en) | 2014-10-23 | 2017-05-30 | Ngm Biopharmaceuticals Inc | Pharmaceutical compositions comprising peptide variants and methods of use thereof |
| US10434144B2 (en) | 2014-11-07 | 2019-10-08 | Ngm Biopharmaceuticals, Inc. | Methods for treatment of bile acid-related disorders and prediction of clinical sensitivity to treatment of bile acid-related disorders |
| DK3236991T3 (da) * | 2014-12-23 | 2019-08-26 | Novo Nordisk As | Fgf21-derivater og anvendelser deraf |
| WO2016110518A1 (en) | 2015-01-07 | 2016-07-14 | Universitat Autònoma De Barcelona | Single-vector gene construct comprising insulin and glucokinase genes |
| KR20160088656A (ko) * | 2015-01-16 | 2016-07-26 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| US10800843B2 (en) | 2015-07-29 | 2020-10-13 | Ngm Biopharmaceuticals, Inc. | Beta klotho-binding proteins |
| CA3000697A1 (en) * | 2015-10-01 | 2017-04-06 | Amgen Inc. | Treatment of bile acid disorders |
| KR102670157B1 (ko) | 2015-10-28 | 2024-05-29 | 주식회사유한양행 | 이중 작용 단백질 및 이를 포함하는 약학적 조성물 |
| KR102668200B1 (ko) * | 2015-10-28 | 2024-05-23 | 주식회사유한양행 | 지속형 fgf21 융합 단백질 및 이를 포함하는 약학적 조성물 |
| WO2017075260A1 (en) | 2015-10-30 | 2017-05-04 | Salk Institute For Biological Studies | Treatment of steroid-induced hyperglycemia with fibroblast growth factor (fgf) 1 analogs |
| ES2871036T3 (es) * | 2015-11-09 | 2021-10-28 | Ngm Biopharmaceuticals Inc | Método para el tratamiento de trastornos relacionados con ácidos biliares |
| US20190142963A1 (en) * | 2016-04-15 | 2019-05-16 | Richard D. DiMarchi | Fgf21 c-terminal peptide optimization |
| MX2018014256A (es) * | 2016-05-20 | 2019-08-16 | Harvard College | Metodos de terapia genica para enfermedades y condiciones relacionadas con la edad. |
| AU2017315459B2 (en) | 2016-08-26 | 2023-06-29 | Ngm Biopharmaceuticals, Inc. | Methods of treating fibroblast growth factor 19-mediated cancers and tumors |
| WO2018088838A1 (en) | 2016-11-10 | 2018-05-17 | Yuhan Corporation | Pharmaceutical composition for preventing or treating hepatitis, hepatic fibrosis, and hepatic cirrhosis comprising fusion proteins |
| CN108570109B (zh) | 2017-03-14 | 2022-04-26 | 广东东阳光药业有限公司 | 包含免疫球蛋白Fc部分的双靶点融合蛋白 |
| CN110709520B (zh) | 2017-04-21 | 2024-04-05 | 株式会社柳韩洋行 | 用于产生双功能蛋白质及其衍生物的方法 |
| CN107056925B (zh) * | 2017-04-28 | 2022-01-14 | 中国科学院合肥物质科学研究院 | 人fgf21突变体、其制备方法及用途 |
| EP3630160A1 (en) * | 2017-05-24 | 2020-04-08 | Universitat Autònoma De Barcelona | Viral expression construct comprising a fibroblast growth factor 21 (fgf21) coding sequence |
| IL270882B2 (en) * | 2017-05-24 | 2024-02-01 | Univ Barcelona Autonoma | Viral expression vectors containing the coding sequence for FIBROBLAST GROWTH FACTOR 21 (FGF21 |
| CN119386161A (zh) | 2017-12-22 | 2025-02-07 | 诺华股份有限公司 | 用fgf21变体治疗代谢障碍的方法 |
| JP7475276B2 (ja) | 2018-02-08 | 2024-04-26 | サンシャイン・レイク・ファーマ・カンパニー・リミテッド | Ｆｇｆ２１バリアント、融合タンパク質及びそれらの適用 |
| CN111944055B (zh) | 2019-05-16 | 2022-08-02 | 浙江道尔生物科技有限公司 | 一种治疗代谢疾病的融合蛋白 |
| US11542309B2 (en) | 2019-07-31 | 2023-01-03 | Salk Institute For Biological Studies | Fibroblast growth factor 1 (FGF1) mutant proteins that selectively activate FGFR1B to reduce blood glucose |
| CN113366024B (zh) * | 2020-01-08 | 2024-11-05 | 上海翰森生物医药科技有限公司 | Fgf21突变体蛋白及其融合蛋白 |
| WO2021139744A1 (en) | 2020-01-11 | 2021-07-15 | Beijing Ql Biopharmaceutical Co., Ltd. | Conjugates of fusion proteins of glp-1 and fgf21 |
| EP4288461A4 (en) | 2021-07-14 | 2025-07-02 | Beijing Ql Biopharmaceutical Co Ltd | FUSION POLYPEPTIDES FOR METABOLIC DISORDERS |
| CN113980147B (zh) * | 2021-11-26 | 2023-07-28 | 中国药科大学 | 一种聚多肽与fgf21融合蛋白突变体及其应用 |
| IL319173A (en) * | 2022-09-12 | 2025-04-01 | Akero Therapeutics Inc | Mutant FGF21 polypeptides |
| KR20250075704A (ko) | 2022-09-30 | 2025-05-28 | 익스텐드 바이오사이언시즈, 인크. | 장기-지속형 부갑상선 호르몬 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3773919A (en) | 1969-10-23 | 1973-11-20 | Du Pont | Polylactide-drug mixtures |
| US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
| US4263428A (en) | 1978-03-24 | 1981-04-21 | The Regents Of The University Of California | Bis-anthracycline nucleic acid function inhibitors and improved method for administering the same |
| JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
| IE52535B1 (en) | 1981-02-16 | 1987-12-09 | Ici Plc | Continuous release pharmaceutical compositions |
| US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
| EP0088046B1 (de) | 1982-02-17 | 1987-12-09 | Ciba-Geigy Ag | Lipide in wässriger Phase |
| HUT35524A (en) | 1983-08-02 | 1985-07-29 | Hoechst Ag | Process for preparing pharmaceutical compositions containing regulatory /regulative/ peptides providing for the retarded release of the active substance |
| US4615885A (en) | 1983-11-01 | 1986-10-07 | Terumo Kabushiki Kaisha | Pharmaceutical composition containing urokinase |
| US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
| EP0154316B1 (en) | 1984-03-06 | 1989-09-13 | Takeda Chemical Industries, Ltd. | Chemically modified lymphokine and production thereof |
| DE3675588D1 (de) | 1985-06-19 | 1990-12-20 | Ajinomoto Kk | Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist. |
| US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
| ATE106249T1 (de) | 1987-11-05 | 1994-06-15 | Hybritech Inc | Polysaccharidmodifizierte immunglobuline mit reduziertem immunogenem potential oder verbesserter pharmakokinetik. |
| WO1990006952A1 (fr) | 1988-12-22 | 1990-06-28 | Kirin-Amgen, Inc. | Facteur de stimulation de colonies de granulocytes modifies chimiquement |
| US5252714A (en) | 1990-11-28 | 1993-10-12 | The University Of Alabama In Huntsville | Preparation and use of polyethylene glycol propionaldehyde |
| US6565841B1 (en) | 1991-03-15 | 2003-05-20 | Amgen, Inc. | Pulmonary administration of granulocyte colony stimulating factor |
| WO1993015722A1 (en) | 1992-02-07 | 1993-08-19 | Syntex (Usa) Inc. | Controlled delivery of pharmaceuticals from preformed porous microparticles |
| US5234784A (en) | 1992-04-01 | 1993-08-10 | Eastman Kodak Company | Method of making a projection viewable transparency comprising an electrostatographic toner image |
| US5824784A (en) | 1994-10-12 | 1998-10-20 | Amgen Inc. | N-terminally chemically modified protein compositions and methods |
| US6133426A (en) | 1997-02-21 | 2000-10-17 | Genentech, Inc. | Humanized anti-IL-8 monoclonal antibodies |
| WO2003011213A2 (en) * | 2001-07-30 | 2003-02-13 | Eli Lilly And Company | Method for treating diabetes and obesity |
| MX2007004074A (es) | 2004-10-07 | 2007-08-14 | Univ California | Analogos de toxina shk y sus usos en inhibicion selectiva de canales de potasio kv1.3. |
| EP2068909B1 (en) * | 2007-03-30 | 2012-04-25 | Ambrx, Inc. | Modified fgf-21 polypeptides and their uses |
| JOP20190083A1 (ar) * | 2008-06-04 | 2017-06-16 | Amgen Inc | بولي ببتيدات اندماجية طافرة لـfgf21 واستخداماتها |
| EA032727B1 (ru) * | 2008-10-10 | 2019-07-31 | Амген Инк. | Мутантный резистентный к протеолизу полипептид fgf21 и его применение |
| EP2427207B1 (en) * | 2009-05-05 | 2017-08-16 | Amgen, Inc | Fgf21 mutants and uses thereof |
| MY156542A (en) * | 2009-05-05 | 2016-02-26 | Amgen Inc | Fgf21 mutants and uses thereof |
| JP2012530493A (ja) | 2009-06-17 | 2012-12-06 | アムジエン・インコーポレーテツド | キメラポリペプチドおよびその使用 |
| WO2011068893A1 (en) | 2009-12-02 | 2011-06-09 | Amgen Inc. | BINDING PROTEINS THAT BIND TO HUMAN FGFR1C, HUMAN β-KLOTHO AND BOTH HUMAN FGFR1C AND HUMANβ-KLOTHO |
| UA109888C2 (uk) | 2009-12-07 | 2015-10-26 | ІЗОЛЬОВАНЕ АНТИТІЛО АБО ЙОГО ФРАГМЕНТ, ЩО ЗВ'ЯЗУЄТЬСЯ З β-КЛОТО, РЕЦЕПТОРАМИ FGF І ЇХНІМИ КОМПЛЕКСАМИ | |
| WO2011130417A2 (en) | 2010-04-15 | 2011-10-20 | Amgen Inc. | HUMAN FGF RECEPTOR AND β-KLOTHO BINDING PROTEINS |
| EP2548570A1 (en) * | 2011-07-19 | 2013-01-23 | Sanofi | Pharmaceutical composition for treating a metabolic syndrome |
-
2012
- 2012-08-30 JP JP2014528614A patent/JP2014526441A/ja active Pending
- 2012-08-30 MX MX2014002260A patent/MX2014002260A/es unknown
- 2012-08-30 US US14/241,848 patent/US20140213512A1/en not_active Abandoned
- 2012-08-30 AU AU2012301769A patent/AU2012301769B2/en active Active
- 2012-08-30 WO PCT/US2012/053216 patent/WO2013033452A2/en not_active Ceased
- 2012-08-30 EP EP12766746.7A patent/EP2750695A2/en not_active Withdrawn
- 2012-08-30 CA CA2845357A patent/CA2845357A1/en not_active Abandoned
-
2017
- 2017-07-06 JP JP2017132449A patent/JP2017226665A/ja active Pending
- 2017-08-08 US US15/671,923 patent/US20180000898A1/en not_active Abandoned